The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs

Inclusion Criteria Patients must have: * Documented HIV infection. * CD4+ cell count \<= 200 cells/mm3. * Life expectancy \> 3 months. * Written informed consent from parent or guardian for patients \< 18 years of age. * Willingness and ability to follow protocol requirements. Exclusion Criteria Co-existing Condition: Patients with any of the following conditions or symptoms are excluded: Patient is enrolled or plans to enroll during the course of this study in another clinical study of an antiretroviral or other agent used to treat HIV-1 infection. * NOTE: * Patients are allowed to participate in opportunistic infection clinical studies if the investigational agent is not contraindicated for the study. Concurrent Medication: Excluded: * Patient is receiving therapy with an antiretroviral agent other than ZDV, d4T, ddI, ddC, or 3TC. * Patient is receiving acute therapy for a clinical AIDS progression event such as systemic chemotherapy. * Dicumarol, Warfarin and other anticoagulant medications. * Tolbutamide. * Investigational drugs (unless included in opportunistic infection clinical trial) and all antiretroviral agents (excluding ZDV, ddC, ddI, d4T and 3TC). * Neurotoxic drugs. * Cimetidine. * Erythromycin. Concurrent Treatment: Excluded: Radiation therapy. Patients with any of the following prior conditions and symptoms are excluded: History of clinically important disease other than HIV-1 infection or related diseases that, in the opinion of the investigator, may put the patient at risk because of participation in this study. Prior Medication: Excluded: * Patient has received prior therapy with Viramune or any other non-nucleoside reverse transcriptase inhibitor. * Patient has received any immunosuppressive or cytotoxic drugs or any other experimental agent within 4 weeks prior to study day 1. * Patient has received treatment with erythromycin, coumadin/warfarin, phenobarbital, amoxicillin/clavulanic acid, or ticarcillin/clavulanic acid within 2 weeks prior to study day 0. Risk Behavior: Excluded: Patients who are active chronic alcohol or substance abusers or have an active psychiatric condition sufficient to impair compliance with protocol requirements. Required: Patient must be receiving stable nucleoside therapy with at least one agent for \>= 4 weeks prior to study day 0. Zidovudine (ZDV), Zidovudine + Dideoxycytidine (ddC), or Zidovudine + Didanosine (ddI) must be used unless prior intolerance precludes ZDV use. Stable use means no change in dose \> 50% for any background nucleoside within four weeks prior to study day 0. NOTE: * If patient is ZDV intolerant, ddC, ddI or D4T monotherapy is allowed.